| Literature DB >> 33804207 |
José Antonio Mingorance1,2, Pedro Montoya1, José García Vivas Miranda3, Inmaculada Riquelme1,2.
Abstract
Whole body vibration has been proven to improve the health status of patients with fibromyalgia, providing an activation of the neuromuscular spindles, which are responsible for muscle contraction. The present study aimed to compare the effectiveness of two types of whole body vibrating platforms (vertical and rotational) during a 12-week training program. Sixty fibromyalgia patients (90% were women) were randomly assigned to one of the following groups: group A (n = 20), who performed the vibration training with a vertical platform; group B (n = 20), who did rotational platform training; or a control group C (n = 20), who did not do any training. Sensitivity measures (pressure pain and vibration thresholds), quality of life (Quality of Life Index), motor function tasks (Berg Scale, six-minute walking test, isometric back muscle strength), and static and dynamic balance (Romberg test and gait analysis) were assessed before, immediately after, and three months after the therapy program. Although both types of vibration appeared to have beneficial effects with respect to the control group, the training was more effective with the rotational than with vertical platform in some parameters, such as vibration thresholds (p < 0.001), motor function tasks (p < 0.001), mediolateral sway (p < 0.001), and gait speed (p < 0.05). Nevertheless, improvements disappeared in the follow-up in both types of vibration. Our study points out greater benefits with the use of rotational rather than vertical whole body vibration. The use of the rotational modality is recommended in the standard therapy program for patients with fibromyalgia. Due to the fact that the positive effects of both types of vibration disappeared during the follow-up, continuous or intermittent use is recommended.Entities:
Keywords: chronic pain; postural balance; proprioception; quality of life
Year: 2021 PMID: 33804207 PMCID: PMC8001601 DOI: 10.3390/ijerph18063007
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1CONSORT flow diagram.
Sociodemographic data from the intervention and control groups. Sd: standard deviation, BMI: body mass index.
| CG ( | RWBV ( | VWBV ( | ||
|---|---|---|---|---|
| Mean ± sd | Mean ± sd | Mean ± sd |
| |
| Age (years) | 50.25 ± 8.53 | 52.30 ± 8.04 | 54.85 ± 8.62 | 0.23 |
| BMI | 23.34 ± 1.23 | 22.95 ± 1.30 | 24.21 ± 3.93 | 0.27 |
| Height (centimeters) | 169.15 ± 6.41 | 168.25 ± 6.35 | 166.90 ± 7.86 | 0.58 |
| Weight (kilograms) | 67.00 ± 7.46 | 65.05 ± 5.82 | 67.00 ± 7.43 | 0.59 |
| Pain duration (years) | 7.50 ± 3.22 | 6.75 ± 2.29 | 7.90 ± 2.82 | 0.42 |
CG: control group; RWBV: rotational whole body vibration; VWBV: vertical whole body vibration.
Comparisons results.
| Dependent Variables | Vertical Group ( | Rotational Group ( | Control Group ( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | After | Follow-up | Baseline | After | Follow-up | Baseline | After | Follow-up | |
| Fibromyalgia Impact Questionnaire | 81.07 (77.74–84.39) | 77.68 (74.36–81.00) | 80.73 (77.22–84.24) | 81.87 (75.84–87.91) | 69.37 (62.24–76.50) | 81.00 (74.70–87.32) | 81.44 (78.30–84.58) | 81.72 (78.61–84.82) | 81.67 (78.63–84.71) |
| Visual Analogue Pain Scale | 7.72 (7.48–7.97) | 7.47 (7.19–7.76) | 7.77 (7.54–8.00) | 7.75 (7.54–7.96) | 7.12 (6.75–7.49) | 7.81 (7.55–8.07) | 7.80 (7.55–8.04) | 7.80 (7.55–8.04) | 7.78 (7.56–8.01) |
| Quality of Life Index | 3.80 (3.32–4.27) | 4.20 (3.81–4.59) | 3.85 (3.39–4.31) | 3.75 (3.35–4.15) | 5.00 (4.54–5.45) | 3.80 (3.33–4.27) | 3.85 (3.34–4.36) | 3.80 (3.33–4.27) | 3.75 (3.25–4.25) |
| Pressure pain sensitivity epicondyles | 21.45 (16.56–26.35) | 22.95 (17.99–27.92) | 21.65 (16.89–26.42) | 21.07 (17.16–24.98) | 29.81 (25.24–34.38) | 21.49 (17.65–25.32) | 21.90 (18.77–25.03) | 22.19 (19.25–25.13) | 22.04 (18.83–25.25) |
| Pressure pain sensitivity index fingers | 36.08 (28.92–43.24) | 38.36 (30.98–45.75) | 35.77 (28.51–43.02) | 35.33 (30.49–40.16) | 47.21 (43.19–51.22) | 35.81 (31.33–40.30) | 35.45 (29.24–41.66) | 35.32 (28.95–41.68) | 35.49 (29.25–41.73) |
| Vibration thresholds index fingers | 3.61 (3.11–4.12) | 3.40 (2.92–3.88) | 3.64 (3.14–4.13) | 3.52 (3.11–3.93) | 2.84 (2.48–3.21) | 3.57 (3.20–3.93) | 3.57 (3.32–3.82) | 3.52 (3.22–3.82) | 3.55 (3.26–3.85) |
| Vibration thresholds toes | 4.40 (3.89–4.90) | 4.28 (3.78–4.78) | 4.37 (3.86–4.87) | 4.37 (3.94–4.81) | 3.68 (3.30–4.07) | 4.43 (3.88–4.98) | 4.51 (4.27–4.74) | 4.50 (4.24–4.76) | 4.50 (4.25–4.75) |
| Berg Scale | 27.95 (25.79–30.11) | 29.60 (27.41–31.79) | 28.15 (26.11–30.19) | 27.00 (24.27–29.73) | 39.10 (36.81–41.39) | 27.25 (24.52–29.98) | 28.15 (26.68–29.62) | 28.45 (27.01–29.89) | 28.40 (26.94–29.86) |
| Six-minute walking test | 385.00 (353.15–416.85) | 394.25 (362.55–425.95) | 382.25 (349.86–414.64) | 365.00 (354.00–376.00) | 415.00 (402.76–427.24) | 358.75 (342.95–374.55) | 391.25 (369.35–413.15) | 387.75 (367.70–407.80) | 383.75 (364.79–402.71) |
| Isometric back muscle strength | 33.85 (31.30–36.40) | 35.70 (33.23–38.17) | 32.75 (30.04–35.46) | 33.40 (31.57–35.23) | 40.85 (38.07–43.63) | 33.45 (31.88–35.02) | 33.05 (30.64–35.46) | 32.85 (30.57–35.13) | 33.10 (29.85–36.35) |
| Mean sway velocity | 0.019 (0.014–0.023) | 0.013 (0.008–0.018) | 0.018 (0.013–0.023) | 0.017 (0.013–0.021) | 0.011 (0.008–0.013) | 0.016 (0.013–0.019) | 0.018 (0.013–0.021) | 0.017 (0.013–0.021) | 0.017 (0.015–0.020) |
| Mediolateral body sway | 0.016 (0.012–0.019) | 0.011 (0.007–0.015) | 0.014 (0.010–0.019) | 0.013 (0.008–0.018) | 0.004 (0.002–0.005) | 0.013 (0.006–0.021) | 0.014 (0.009–0.019) | 0.013 (0.008–0.017) | 0.012 (0.008–0.016) |
| Anteroposterior body sway | 0.013 (0.011–0.015) | 0.012 (0.009–0.014) | 0.013 (0.009–0.016) | 0.015 (0.012–0.017) | 0.013 (0.009–0.016) | 0.015 (0.011–0.019) | 0.013 (0.009–0.016) | 0.012 (0.008–0.016) | 0.012 (0.008–0.016) |
| Gait speed | 3.01 (2.57–3.45) | 3.48 (3.05–3.91) | 3.02 (2.53–3.51) | 2.99 (2.69–3.30) | 3.93 (3.40–4.44) | 3.19 (2.80–3.58) | 3.04 (2.58–3.49) | 3.02 (2.58–3.46) | 3.06 (2.55–3.57) |
| Stride length | 0.97 (0.83–1.13) | 1.00 (0.85–1.15) | 0.93 (0.80–1.06) | 0.88 (0.72–1.03) | 0.95 (0.82–1.08) | 0.93 (0.77–1.08) | 0.93 (0.77–1.10) | 1.13 (0.94–1.31) | 1.05 (0.88–1.22) |
| Percentage of time in the stance phase | 68.30 (65.53–71.07) | 67.41 (65.44–69.37) | 68.76 (66.35–71.16) | 64.75 (57.51–71.99) | 64.84 (60.84–68.85) | 67.56 (65.64–69.47) | 68.48 (65.04–71.91) | 67.56 (63.05–72.07) | 67.94 (64.59–71.29) |
| Percentage of time in the swing phase | 31.69 (28.92–34.47) | 32.59 (30.62–34.55) | 31.24 (28.84–33.64) | 31.77 (29.78–33.76) | 33.45 (31.68–35.22) | 32.44 (30.52–34.35) | 31.52 (28.08–34.95) | 33.93 (30.96–36.90) | 32.25 (28.85–35.65) |
Figure 2Mean of mediolateral body sway (axis X) and mean of anteroposterior body sway (axis Y) in pretreatment, post-treatment, and follow-up for the intervention groups and for the control group.